Innate Pharma 和 IFLI 合作研究滤泡性淋巴瘤的IPH6501，投资高达 $7.9M。 Innate Pharma and IFLI partner to study IPH6501 for follicular lymphoma, with up to $7.9M investment.

原药厂和IFLI已同意研究IPH6501在治疗胎儿淋巴瘤方面的潜力,这是一种抗CD20的药物。 Innate Pharma and IFLI have agreed to study the potential of IPH6501, an anti-CD20 drug, in treating follicular lymphoma. IFLI最初将投资300万美元,用于支持第1/2阶段的试验,可能的总投资达790万美元,用于进一步开发这一疾病的IPH6501。 IFLI will initially invest $3 million to support a Phase 1/2 trial, with the potential total investment reaching up to $7.9 million for further development of IPH6501 in this disease.